Sanofi
SNY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 11.30 | -0.65 | 0.48 | -0.36 |
| FCF Yield | 5.05% | 7.63% | 7.35% | 7.68% |
| EV / EBITDA | 11.51 | 10.82 | 9.01 | 10.63 |
| Quality | ||||
| ROIC | 5.51% | 5.53% | 7.67% | 6.36% |
| Gross Margin | 70.18% | 69.66% | 70.71% | 68.72% |
| Cash Conversion Ratio | 1.65 | 1.90 | 1.26 | 1.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.97% | 2.04% | 2.77% | 1.35% |
| Free Cash Flow Growth | -31.87% | 3.77% | -1.82% | 58.93% |
| Safety | ||||
| Net Debt / EBITDA | 0.95 | 0.88 | 0.63 | 1.07 |
| Interest Coverage | 11.65 | 13.57 | 26.41 | 21.53 |
| Efficiency | ||||
| Inventory Turnover | 1.40 | 1.31 | 1.33 | 1.41 |
| Cash Conversion Cycle | 139.57 | 164.40 | 162.65 | 166.69 |